Human Immunodeficiency Virus Type-1 Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Solutions, Mode, Stage

Description

The global Human Immunodeficiency Virus Type-1 market is projected to grow from $39.2 billion in 2025 to $70.5 billion by 2035, at a compound annual growth rate (CAGR) of 6.0%. The Human Immunodeficiency Virus Type-1 market continues to expand alongside increasing global diagnostic coverage and treatment monitoring requirements. According to UNAIDS, approximately 39.9 million people were living with HIV worldwide in 2023, with around 1.3 million new infections reported during the year. The World Health Organization also supports expanded HIV testing through rapid diagnostics and nucleic acid technologies to improve early detection. Industry assessments indicate the global HIV diagnostics market is projected to grow at a mid-to-high single-digit CAGR over the coming years, supported by government-funded screening programs, technological innovation, and broader laboratory infrastructure investments.

The technology landscape includes PCR testing, ELISA, Western blot, rapid diagnostic tests, and next-generation sequencing (NGS), each serving distinct roles across HIV-1 diagnosis and monitoring. PCR remains the benchmark for viral load quantification and early infection detection, while ELISA is widely adopted for initial antibody screening due to high throughput. Western blot continues to support confirmatory testing in selected settings despite declining routine use. Rapid tests enhance accessibility through decentralized and point-of-care screening. NGS is increasingly utilized for resistance profiling, molecular surveillance, and precision medicine applications. Continuous technological improvements are strengthening diagnostic accuracy, workflow efficiency, and laboratory automation.

Market Segmentation
Type	Antiretroviral Therapy (ART), Pre-Exposure Prophylaxis (PrEP), Post-Exposure Prophylaxis (PEP), Others
Product	Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Integrase Inhibitors, Entry Inhibitors, Fixed-Dose Combinations, Others
Services	Diagnostic Testing, Counseling, Patient Monitoring, Adherence Support, Others
Technology	Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Immunoassays, Point-of-Care Testing, Others
Application	Clinical Treatment, Research and Development, Public Health Programs, Others
End User	Hospitals, Clinics, Research Institutes, Diagnostic Laboratories, Community Health Centers, Others
Solutions	Treatment Solutions, Prevention Solutions, Diagnostic Solutions, Others
Mode	Oral, Injectable, Transdermal, Others
Stage	Acute HIV, Chronic HIV, AIDS, Others

The application segment encompasses clinical diagnostics, research and development, and blood screening. Clinical diagnostics account for the largest utilization due to routine HIV-1 screening, confirmatory testing, treatment monitoring, and viral load assessments in hospitals and diagnostic laboratories. Research and development leverage advanced molecular technologies to investigate viral evolution, therapeutic targets, vaccine candidates, and drug resistance mechanisms. Blood screening ensures transfusion safety by detecting HIV-1 in donated blood using sensitive nucleic acid amplification methods. Growing emphasis on early diagnosis, preventive healthcare, and biomedical innovation continues to expand application opportunities across public health systems and commercial laboratories.

Geographical Overview

North America maintains a leading position in the Human Immunodeficiency Virus Type-1 market due to its advanced healthcare infrastructure, extensive molecular diagnostic capabilities, and well-established reimbursement systems. The region benefits from high adoption of PCR-based diagnostics, next-generation sequencing, and automated laboratory platforms across hospitals and reference laboratories. Strong public health initiatives, continuous funding for HIV prevention and surveillance, and active participation of biotechnology companies strengthen market expansion. Robust clinical research activities, favorable regulatory pathways, and widespread access to antiretroviral therapy further reinforce sustained demand for innovative HIV-1 diagnostic technologies and monitoring solutions.

Asia-Pacific demonstrates substantial market expansion driven by increasing healthcare investments, improving diagnostic accessibility, and rising awareness of HIV prevention programs. Governments across several countries are strengthening disease surveillance, expanding blood screening infrastructure, and promoting early diagnosis through national healthcare initiatives. Growing laboratory modernization, increasing adoption of rapid testing technologies, and investments in molecular diagnostic platforms are supporting broader market penetration. Expanding pharmaceutical research, collaborations between international healthcare organizations and regional institutions, and improving healthcare access create favorable conditions for long-term adoption of advanced HIV-1 testing and surveillance technologies.

Key Trends and Drivers

Molecular Diagnostics and Point-of-Care Testing Reshape HIV-1 Detection:

The market is witnessing increasing adoption of molecular diagnostics and decentralized testing solutions that improve early HIV-1 detection and treatment monitoring. Integration of automated PCR platforms, next-generation sequencing for drug resistance analysis, multiplex diagnostic assays, and digital laboratory information systems is enhancing clinical efficiency. Simultaneously, portable rapid diagnostic tests are expanding access in resource-limited settings, supporting public health objectives aimed at earlier diagnosis and reduced disease transmission.

Global HIV Screening Initiatives and Early Diagnosis Fuel Market Growth:

Growing global initiatives focused on HIV elimination, universal testing, and early treatment are driving sustained demand for advanced HIV-1 diagnostic technologies. Government-funded screening programs, international donor support, expanded access to antiretroviral therapy, and increasing implementation of routine viral load monitoring are encouraging healthcare providers to adopt highly sensitive and accurate testing platforms. Continuous technological advancements further strengthen diagnostic performance and operational efficiency across clinical laboratories.

Research Scope

Estimates and forecasts the overall market size across type, application, and region.
Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

Product Code: GIS26140

1 Executive Summary

1.1 Market Size and Forecast
1.2 Market Overview
1.3 Market Snapshot
1.4 Regional Snapshot
1.5 Strategic Recommendations
1.6 Analyst Notes

2 Market Highlights

2.1 Key Market Highlights by Type
2.2 Key Market Highlights by Product
2.3 Key Market Highlights by Services
2.4 Key Market Highlights by Technology
2.5 Key Market Highlights by Application
2.6 Key Market Highlights by End User
2.7 Key Market Highlights by Mode
2.8 Key Market Highlights by Stage
2.9 Key Market Highlights by Solutions

3 Market Dynamics

3.1 Macroeconomic Analysis
3.2 Market Trends
3.3 Market Drivers
3.4 Market Opportunities
3.5 Market Restraints
3.6 CAGR Growth Analysis
3.7 Impact Analysis
3.8 Emerging Markets
3.9 Technology Roadmap
3.10 Strategic Frameworks
- 3.10.1 PORTER's 5 Forces Model
- 3.10.2 ANSOFF Matrix
- 3.10.3 4P's Model
- 3.10.4 PESTEL Analysis

4 Segment Analysis

4.1 Market Size & Forecast by Type (2020-2035)
- 4.1.1 Antiretroviral Therapy (ART)
- 4.1.2 Pre-Exposure Prophylaxis (PrEP)
- 4.1.3 Post-Exposure Prophylaxis (PEP)
- 4.1.4 Others
4.2 Market Size & Forecast by Product (2020-2035)
- 4.2.1 Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
- 4.2.2 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
- 4.2.3 Protease Inhibitors (PIs)
- 4.2.4 Integrase Inhibitors
- 4.2.5 Entry Inhibitors
- 4.2.6 Fixed-Dose Combinations
- 4.2.7 Others
4.3 Market Size & Forecast by Services (2020-2035)
- 4.3.1 Diagnostic Testing
- 4.3.2 Counseling
- 4.3.3 Patient Monitoring
- 4.3.4 Adherence Support
- 4.3.5 Others
4.4 Market Size & Forecast by Technology (2020-2035)
- 4.4.1 Polymerase Chain Reaction (PCR)
- 4.4.2 Next-Generation Sequencing (NGS)
- 4.4.3 Immunoassays
- 4.4.4 Point-of-Care Testing
- 4.4.5 Others
4.5 Market Size & Forecast by Application (2020-2035)
- 4.5.1 Clinical Treatment
- 4.5.2 Research and Development
- 4.5.3 Public Health Programs
- 4.5.4 Others
4.6 Market Size & Forecast by End User (2020-2035)
- 4.6.1 Hospitals
- 4.6.2 Clinics
- 4.6.3 Research Institutes
- 4.6.4 Diagnostic Laboratories
- 4.6.5 Community Health Centers
- 4.6.6 Others
4.7 Market Size & Forecast by Mode (2020-2035)
- 4.7.1 Oral
- 4.7.2 Injectable
- 4.7.3 Transdermal
- 4.7.4 Others
4.8 Market Size & Forecast by Stage (2020-2035)
- 4.8.1 Acute HIV
- 4.8.2 Chronic HIV
- 4.8.3 AIDS
- 4.8.4 Others
4.9 Market Size & Forecast by Solutions (2020-2035)
- 4.9.1 Treatment Solutions
- 4.9.2 Prevention Solutions
- 4.9.3 Diagnostic Solutions
- 4.9.4 Others

5 Regional Analysis

5.1 Global Market Overview
5.2 North America Market Size (2020-2035)
- 5.2.1 United States
  - 5.2.1.1 Type
  - 5.2.1.2 Product
  - 5.2.1.3 Services
  - 5.2.1.4 Technology
  - 5.2.1.5 Application
  - 5.2.1.6 End User
  - 5.2.1.7 Mode
  - 5.2.1.8 Stage
  - 5.2.1.9 Solutions
- 5.2.2 Canada
  - 5.2.2.1 Type
  - 5.2.2.2 Product
  - 5.2.2.3 Services
  - 5.2.2.4 Technology
  - 5.2.2.5 Application
  - 5.2.2.6 End User
  - 5.2.2.7 Mode
  - 5.2.2.8 Stage
  - 5.2.2.9 Solutions
- 5.2.3 Mexico
  - 5.2.3.1 Type
  - 5.2.3.2 Product
  - 5.2.3.3 Services
  - 5.2.3.4 Technology
  - 5.2.3.5 Application
  - 5.2.3.6 End User
  - 5.2.3.7 Mode
  - 5.2.3.8 Stage
  - 5.2.3.9 Solutions
5.3 Latin America Market Size (2020-2035)
- 5.3.1 Brazil
  - 5.3.1.1 Type
  - 5.3.1.2 Product
  - 5.3.1.3 Services
  - 5.3.1.4 Technology
  - 5.3.1.5 Application
  - 5.3.1.6 End User
  - 5.3.1.7 Mode
  - 5.3.1.8 Stage
  - 5.3.1.9 Solutions
- 5.3.2 Argentina
  - 5.3.2.1 Type
  - 5.3.2.2 Product
  - 5.3.2.3 Services
  - 5.3.2.4 Technology
  - 5.3.2.5 Application
  - 5.3.2.6 End User
  - 5.3.2.7 Mode
  - 5.3.2.8 Stage
  - 5.3.2.9 Solutions
- 5.3.3 Rest of Latin America
  - 5.3.3.1 Type
  - 5.3.3.2 Product
  - 5.3.3.3 Services
  - 5.3.3.4 Technology
  - 5.3.3.5 Application
  - 5.3.3.6 End User
  - 5.3.3.7 Mode
  - 5.3.3.8 Stage
  - 5.3.3.9 Solutions
5.4 Asia-Pacific Market Size (2020-2035)
- 5.4.1 China
  - 5.4.1.1 Type
  - 5.4.1.2 Product
  - 5.4.1.3 Services
  - 5.4.1.4 Technology
  - 5.4.1.5 Application
  - 5.4.1.6 End User
  - 5.4.1.7 Mode
  - 5.4.1.8 Stage
  - 5.4.1.9 Solutions
- 5.4.2 India
  - 5.4.2.1 Type
  - 5.4.2.2 Product
  - 5.4.2.3 Services
  - 5.4.2.4 Technology
  - 5.4.2.5 Application
  - 5.4.2.6 End User
  - 5.4.2.7 Mode
  - 5.4.2.8 Stage
  - 5.4.2.9 Solutions
- 5.4.3 South Korea
  - 5.4.3.1 Type
  - 5.4.3.2 Product
  - 5.4.3.3 Services
  - 5.4.3.4 Technology
  - 5.4.3.5 Application
  - 5.4.3.6 End User
  - 5.4.3.7 Mode
  - 5.4.3.8 Stage
  - 5.4.3.9 Solutions
- 5.4.4 Japan
  - 5.4.4.1 Type
  - 5.4.4.2 Product
  - 5.4.4.3 Services
  - 5.4.4.4 Technology
  - 5.4.4.5 Application
  - 5.4.4.6 End User
  - 5.4.4.7 Mode
  - 5.4.4.8 Stage
  - 5.4.4.9 Solutions
- 5.4.5 Australia
  - 5.4.5.1 Type
  - 5.4.5.2 Product
  - 5.4.5.3 Services
  - 5.4.5.4 Technology
  - 5.4.5.5 Application
  - 5.4.5.6 End User
  - 5.4.5.7 Mode
  - 5.4.5.8 Stage
  - 5.4.5.9 Solutions
- 5.4.6 Taiwan
  - 5.4.6.1 Type
  - 5.4.6.2 Product
  - 5.4.6.3 Services
  - 5.4.6.4 Technology
  - 5.4.6.5 Application
  - 5.4.6.6 End User
  - 5.4.6.7 Mode
  - 5.4.6.8 Stage
  - 5.4.6.9 Solutions
- 5.4.7 Rest of APAC
  - 5.4.7.1 Type
  - 5.4.7.2 Product
  - 5.4.7.3 Services
  - 5.4.7.4 Technology
  - 5.4.7.5 Application
  - 5.4.7.6 End User
  - 5.4.7.7 Mode
  - 5.4.7.8 Stage
  - 5.4.7.9 Solutions
5.5 Europe Market Size (2020-2035)
- 5.5.1 Germany
  - 5.5.1.1 Type
  - 5.5.1.2 Product
  - 5.5.1.3 Services
  - 5.5.1.4 Technology
  - 5.5.1.5 Application
  - 5.5.1.6 End User
  - 5.5.1.7 Mode
  - 5.5.1.8 Stage
  - 5.5.1.9 Solutions
- 5.5.2 France
  - 5.5.2.1 Type
  - 5.5.2.2 Product
  - 5.5.2.3 Services
  - 5.5.2.4 Technology
  - 5.5.2.5 Application
  - 5.5.2.6 End User
  - 5.5.2.7 Mode
  - 5.5.2.8 Stage
  - 5.5.2.9 Solutions
- 5.5.3 United Kingdom
  - 5.5.3.1 Type
  - 5.5.3.2 Product
  - 5.5.3.3 Services
  - 5.5.3.4 Technology
  - 5.5.3.5 Application
  - 5.5.3.6 End User
  - 5.5.3.7 Mode
  - 5.5.3.8 Stage
  - 5.5.3.9 Solutions
- 5.5.4 Spain
  - 5.5.4.1 Type
  - 5.5.4.2 Product
  - 5.5.4.3 Services
  - 5.5.4.4 Technology
  - 5.5.4.5 Application
  - 5.5.4.6 End User
  - 5.5.4.7 Mode
  - 5.5.4.8 Stage
  - 5.5.4.9 Solutions
- 5.5.5 Italy
  - 5.5.5.1 Type
  - 5.5.5.2 Product
  - 5.5.5.3 Services
  - 5.5.5.4 Technology
  - 5.5.5.5 Application
  - 5.5.5.6 End User
  - 5.5.5.7 Mode
  - 5.5.5.8 Stage
  - 5.5.5.9 Solutions
- 5.5.6 Rest of Europe
  - 5.5.6.1 Type
  - 5.5.6.2 Product
  - 5.5.6.3 Services
  - 5.5.6.4 Technology
  - 5.5.6.5 Application
  - 5.5.6.6 End User
  - 5.5.6.7 Mode
  - 5.5.6.8 Stage
  - 5.5.6.9 Solutions
5.6 Middle East & Africa Market Size (2020-2035)
- 5.6.1 Saudi Arabia
  - 5.6.1.1 Type
  - 5.6.1.2 Product
  - 5.6.1.3 Services
  - 5.6.1.4 Technology
  - 5.6.1.5 Application
  - 5.6.1.6 End User
  - 5.6.1.7 Mode
  - 5.6.1.8 Stage
  - 5.6.1.9 Solutions
- 5.6.2 United Arab Emirates
  - 5.6.2.1 Type
  - 5.6.2.2 Product
  - 5.6.2.3 Services
  - 5.6.2.4 Technology
  - 5.6.2.5 Application
  - 5.6.2.6 End User
  - 5.6.2.7 Mode
  - 5.6.2.8 Stage
  - 5.6.2.9 Solutions
- 5.6.3 South Africa
  - 5.6.3.1 Type
  - 5.6.3.2 Product
  - 5.6.3.3 Services
  - 5.6.3.4 Technology
  - 5.6.3.5 Application
  - 5.6.3.6 End User
  - 5.6.3.7 Mode
  - 5.6.3.8 Stage
  - 5.6.3.9 Solutions
- 5.6.4 Sub-Saharan Africa
  - 5.6.4.1 Type
  - 5.6.4.2 Product
  - 5.6.4.3 Services
  - 5.6.4.4 Technology
  - 5.6.4.5 Application
  - 5.6.4.6 End User
  - 5.6.4.7 Mode
  - 5.6.4.8 Stage
  - 5.6.4.9 Solutions
- 5.6.5 Rest of MEA
  - 5.6.5.1 Type
  - 5.6.5.2 Product
  - 5.6.5.3 Services
  - 5.6.5.4 Technology
  - 5.6.5.5 Application
  - 5.6.5.6 End User
  - 5.6.5.7 Mode
  - 5.6.5.8 Stage
  - 5.6.5.9 Solutions

6 Market Strategy

6.1 Demand-Supply Gap Analysis
6.2 Trade & Logistics Constraints
6.3 Price-Cost-Margin Trends
6.4 Market Penetration
6.5 Consumer Analysis
6.6 Regulatory Snapshot

7 Competitive Intelligence

7.1 Market Positioning
7.2 Market Share
7.3 Competition Benchmarking
7.4 Top Company Strategies

8 Company Profiles

8.1 Gilead Sciences
- 8.1.1 Overview
- 8.1.2 Product Summary
- 8.1.3 Financial Performance
- 8.1.4 SWOT Analysis
8.2 ViiV Healthcare
- 8.2.1 Overview
- 8.2.2 Product Summary
- 8.2.3 Financial Performance
- 8.2.4 SWOT Analysis
8.3 Janssen Pharmaceuticals
- 8.3.1 Overview
- 8.3.2 Product Summary
- 8.3.3 Financial Performance
- 8.3.4 SWOT Analysis
8.4 Merck & Co
- 8.4.1 Overview
- 8.4.2 Product Summary
- 8.4.3 Financial Performance
- 8.4.4 SWOT Analysis
8.5 Roche
- 8.5.1 Overview
- 8.5.2 Product Summary
- 8.5.3 Financial Performance
- 8.5.4 SWOT Analysis
8.6 AbbVie
- 8.6.1 Overview
- 8.6.2 Product Summary
- 8.6.3 Financial Performance
- 8.6.4 SWOT Analysis
8.7 Bristol Myers Squibb
- 8.7.1 Overview
- 8.7.2 Product Summary
- 8.7.3 Financial Performance
- 8.7.4 SWOT Analysis
8.8 GlaxoSmithKline
- 8.8.1 Overview
- 8.8.2 Product Summary
- 8.8.3 Financial Performance
- 8.8.4 SWOT Analysis
8.9 Pfizer
- 8.9.1 Overview
- 8.9.2 Product Summary
- 8.9.3 Financial Performance
- 8.9.4 SWOT Analysis
8.10 Cipla
- 8.10.1 Overview
- 8.10.2 Product Summary
- 8.10.3 Financial Performance
- 8.10.4 SWOT Analysis
8.11 Mylan
- 8.11.1 Overview
- 8.11.2 Product Summary
- 8.11.3 Financial Performance
- 8.11.4 SWOT Analysis
8.12 Teva Pharmaceutical Industries
- 8.12.1 Overview
- 8.12.2 Product Summary
- 8.12.3 Financial Performance
- 8.12.4 SWOT Analysis
8.13 Sun Pharmaceutical Industries
- 8.13.1 Overview
- 8.13.2 Product Summary
- 8.13.3 Financial Performance
- 8.13.4 SWOT Analysis
8.14 Aurobindo Pharma
- 8.14.1 Overview
- 8.14.2 Product Summary
- 8.14.3 Financial Performance
- 8.14.4 SWOT Analysis
8.15 Dr Reddy's Laboratories
- 8.15.1 Overview
- 8.15.2 Product Summary
- 8.15.3 Financial Performance
- 8.15.4 SWOT Analysis
8.16 Hetero Drugs
- 8.16.1 Overview
- 8.16.2 Product Summary
- 8.16.3 Financial Performance
- 8.16.4 SWOT Analysis
8.17 Lupin Limited
- 8.17.1 Overview
- 8.17.2 Product Summary
- 8.17.3 Financial Performance
- 8.17.4 SWOT Analysis
8.18 Amgen
- 8.18.1 Overview
- 8.18.2 Product Summary
- 8.18.3 Financial Performance
- 8.18.4 SWOT Analysis
8.19 Vertex Pharmaceuticals
- 8.19.1 Overview
- 8.19.2 Product Summary
- 8.19.3 Financial Performance
- 8.19.4 SWOT Analysis
8.20 Boehringer Ingelheim
- 8.20.1 Overview
- 8.20.2 Product Summary
- 8.20.3 Financial Performance
- 8.20.4 SWOT Analysis

9 About Us

9.1 About Us
9.2 Research Methodology
9.3 Research Workflow
9.4 Consulting Services
9.5 Our Clients
9.6 Client Testimonials
9.7 Contact Us